BREAKING NEWS
This content is not available in your region

Roche sees 2019 sales, profit rise despite competition from copies

Roche sees 2019 sales, profit rise despite competition from copies
FILE PHOTO - The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann   -   Copyright  Arnd Wiegmann(Reuters)
Text size Aa Aa

By John Miller

ZURICH (Reuters) – Swiss drugmaker Roche expects sales and earnings to rise in 2019, Chief Executive Severin Schwan said on Thursday, even as more copies of the company’s $22 billion trio of cancer medicines Rituxan, Herceptin and Avastin hit the market.

Core operating profit last year rose 9 percent to 20.5 billion Swiss francs ($20.65 billion), Roche said in a statement.

Sales rose 7 percent to 56.8 billion francs, just ahead of the 56.4 billion francs average estimate in a Reuters poll.

Schwan forecast 2019 sales and earnings-per-share growth in the “low- to mid-single digit” percentage range, spurred by new drugs including Ocrevus multiple sclerosis drug, Hemlibra for hemophilia A and cancer medicines Alecensa and Tecentriq.

“Based on the successful launches and our strong product pipeline, Roche is well positioned for continued growth,” Schwan said.

The company board proposed a dividend increase to 8.70 francs per share.

(Reporting by John Miller; Editing by Subhranshu Sahu)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.